Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1710 • ACR Convergence 2023
Genetic Associations in Juvenile Idiopathic Arthritis Determined with an Electronic Health Record Based Approach
Elizabeth Jasper, Srushti Gangireddy, Henry Ong, Jacklyn Hellwege, Todd Edwards, Digna Velez Edwards, Wei-Qi Wei and Anna Patrick, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses multiple forms of pediatric autoimmune arthritis. Research studies in JIA are complicated by disease heterogeneity and difficulties gathering large…
Abstract Number: 2055 • ACR Convergence 2023
A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study
Racheal Githumbi¹, Susan Kuhn¹, Carla Osiowy², Jennifer DeBruyn¹, Marvin Fritzler¹, Nicole Johnson¹, Otto G Vanderkooi¹ and Heinrike Schmeling¹, ¹University of Calgary, Calgary, AB, Canada, ²National Microbiology Laboratory, Public Health Agency of Canada, Winnepig, MB, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) and Crohn's disease (CD) are now controlled using immunosuppressive medications. However, disease control comes at the risk of increased infection.…
Abstract Number: PP11 • ACR Convergence 2023
We Suffered For Decades, But Then She Was Born
Ian Stedman¹ and Barbara Stedman², ¹Canadian Autoinflammatory Network, Vaughan, ON, Canada, ²Canadian Autoinflammatory Network, Turkey Point, ON, Canada
Background/Purpose: I was born in 1981; my mother in 1949; and my grandmother in 1926. Our story runs at least four generations deep, that we…
Abstract Number: 0356 • ACR Convergence 2023
PRINTO Provisional Enthesitis/Spondylitis-Related JIA Criteria: Performance in Youth Classified as Axial Disease in Juvenile Spondyloarthritis
Pamela F. Weiss¹, Timothy G. Brandon², Amita Aggarwal³, RUBEN BURGOS-VARGAS⁴, Robert Colbert⁵, Gerd Horneff⁶, Rik Joos⁷, Ronald Laxer⁸, Kirsten Minden⁹, Angelo Ravelli¹⁰, Nicolino Ruperto¹¹, Judith Smith¹², Matthew Stoll¹³, Shirley Tse⁸, Filip Van den Bosch¹⁴, Walter P. Maksymowych¹⁵, Robert Lambert¹⁶, David Biko², Nancy A. Chauvin¹⁷, Michael L. Francavilla¹⁸, Jacob Jaremko¹⁵, Nele Herregods¹⁹, Ozgur Kasapcopur²⁰, Mehmet YILDIZ²¹, Hemalatha Srinivasalu²², Ray Naden²³ and Alison Hendry²⁴, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁴Hospital General de Mexico, Ciudad de México, Mexico, ⁵NIH/NIAMS, Bethesda, MD, ⁶Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, ⁷Ghent University, Basel, Switzerland, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Charité University Medicine and German Rheumatism Research Center Berlin, Berlin, Germany, ¹⁰Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹¹IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, ¹²University of Wisconsin, Madison, WI, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ¹⁵University of Alberta, Edmonton, AB, Canada, ¹⁶Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ¹⁷The Cleveland Clinic, Hummelstown, PA, ¹⁸University of South Alabama College of Medicine, Mobile, AL, ¹⁹Ghent University Hospital, Ghent, Belgium, ²⁰Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ²¹Istanbul University-Cerrahpasa Department of Pediatric Rheumatology, Istanbul, Turkey, ²²Children's National Hospital, Washington, DC, ²³Auckland City Hospital, Auckland, New Zealand, ²⁴Te Whatu Ora, Counties Manukau District, Middlemore Hospital, Auckland, New Zealand
Background/Purpose: The Paediatric Rheumatology International Trials Organisation (PRINTO) recently undertook an effort to better harmonize the pediatric and adult arthritis criteria. These provisional criteria are…
Abstract Number: 0566 • ACR Convergence 2023
Characterization of Disease Activity Using a Novel Physiologic Biomarker in Pediatric SLE
Sangeeta Sule, Olivia Lamanna, Kevin Jackson, Sun-Young Ahn, Tineer Ahmed and Julia Finkel, Children's National Hospital, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex inflammatory disease involving many organ systems. To better understand and treat SLE, two phenotypes have been proposed.…
Abstract Number: 1205 • ACR Convergence 2023
Universal Social Determinants of Health Screening in a Pediatric Rheumatology Specialty Clinic: A Feasibility Study
Mia Chandler¹, Margart Taggart², Maria Alfieri², Olha Halyabar³, Joyce Chang², Mary Beth Son⁴ and Melissa Hazen², ¹Boston Children's Hospital, Milton, MA, ²Boston Children's Hospital, Boston, MA, ³Children's Hospital/Boston Medical Center, Newton, MA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Social determinants of health (SDoH) significantly impact health outcomes. Practice guidelines from a national pediatric organization and federal agencies recommend routine assessment of SDoH.…
Abstract Number: 1236 • ACR Convergence 2023
Melanoma Differentiation-Associated Protein-5 in Juvenile Dermatomyositis: A Single Center Cohort
Dawn Gist¹, Sarah Molina², Maria Pereira³, Andrea Ramirez³, Cagri Yildirim-Toruner⁴ and Marietta De Guzman³, ¹Baylor College of Medicine Pediatrics Residency, Houston, TX, ²Baylor College of Medicine - Pediatrics Residency Program, Houston, TX, ³Baylor College of Medicine, Houston, TX, ⁴Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy that causes muscle weakness, rash, vascular changes, or other organ involvement. The phenotypes may vary, and…
Abstract Number: 1256 • ACR Convergence 2023
Self-esteem and Body Image of Young People with Rheumatic Diseases: A Systematic Review
Leticia Leon¹, Daniel clemente Garulo², Carmen Heredia³ and lydia Abasolo⁴, ¹Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ²Pediatric Rheumatology Unit, Hospital Niño Jesús, Madrid, Spain, ³Universidad Camilo Jose Cela, Madrid, Spain, ⁴Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Little is known about the self-esteem and body image impact in young people with rheumatic and musculoskeletal diseases (RMD). Studies in chronic illness suggest…
Abstract Number: 1961 • ACR Convergence 2023
Anti-PM/Scl Autoantibodies in Juvenile Myositis Are Associated with a Distinct Phenotype Resembling Anti-synthetase Syndrome
Matthew Sherman¹, Payam Noroozi Farhad², Edward Trieu³, Katherine Pak⁴, Iago Pinal-Fernandez⁴, Kakali Sarkar², Megan Neely⁵, Ira Targoff⁶, Frederick Miller⁷, Andrew Mammen⁸ and Lisa Rider⁹, ¹NIAMS/NIH, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴National Institutes of Health, Bethesda, MD, ⁵Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, ⁶Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷NIH, NIEHS, Chapel Hill, NC, ⁸NIH, Bethesda, MD, ⁹NIEHS, NIH, Bethesda, MD
Background/Purpose: Anti-PM/Scl autoantibodies (Abs) are an uncommon myositis-associated autoantibody (MAA) in juvenile myositis. The clinical features and outcomes associated with anti-PM/Scl Abs in juvenile myositis…
Abstract Number: 2057 • ACR Convergence 2023
Medical Trauma and Its Association with Pain and Disability Risk in Children with Inflammatory Arthritis
Leah Medrano¹, Brenda Bursch¹, Jennifer Weiss², Alice Hoftman¹, Joshua Li³, Nicholas Jackson³ and Deborah McCurdy¹, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Hackensack Meridian School of Medicine, Hackensack, NJ, ³Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: This study aims to determine the prevalence of medical trauma and its impacts on outcomes in a sample of children with inflammatory arthritis. We…
Abstract Number: PP14 • ACR Convergence 2023
Putting Lived Experience into Action: Flipping the Script on Living with a Chronic Disease
Natasha Trehan¹ and Naomi Abrahams², ¹University of Ottawa, Take a Pain Check Foundation, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Naomi was diagnosed with Juvenile Idiopathic Arthritis (JIA) at the age of 18, after enduring 3 years of misdiagnoses. Similarly, Natasha received a diagnosis…
Abstract Number: 016 • 2023 Pediatric Rheumatology Symposium
Gene Expression Changes in Polyarticular Juvenile Idiopathic Arthritis Following Tofacitinib Treatment
Esraa Eloseily¹, Alex Pickering², Sanjeev Dhakal³, Alexei Grom³, Hermine Brunner³ and Sherry Thornton⁴, ¹Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnti, OH, ²Department of Biomedical Informatics, Harvard Medical School, Boston, MA, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Despite advances in the understanding of juvenile idiopathic arthritis (JIA) pathophysiology, personalized treatments informed by gene transcriptomic profiles remain elusive. We aimed toexamine the…
Abstract Number: 054 • 2023 Pediatric Rheumatology Symposium
Craniofacial Localized Scleroderma: A Single Center Retrospective Cohort
Leigh Stubbs, Ammar Hashemi, Raegan Hunt and Renata Maricevich, Baylor College of Medicine, Houston, TX
Background/Purpose: Craniofacial localized scleroderma (LS) can lead to disfigurement and severe extracutaneous manifestations (ECMs). There is an ongoing need to standardize multidisciplinary evaluation and care.…
Abstract Number: 090 • 2023 Pediatric Rheumatology Symposium
Safety Outcomes of Combined Biologics Use in Pediatric Rheumatology: A Single Center Experience
Angela Chun¹, MaiLan Nguyen¹, Marietta De Guzman² and Andrea Ramirez³, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: The management of pediatric rheumatic disease has been forever changed by the advent of biologic drugs and the pursuit of targeted therapy. There is…
Abstract Number: 130 • 2023 Pediatric Rheumatology Symposium
Levels of Neutrophil Extracellular Traps Correlate with Disease Activity in Pediatric Lupus
Lydia Thomas¹, Jenna Battaglia², Bharati Matta³, Kim Simpfendorfer⁴, Joyce Hui-Yuen⁵ and Betsy Barnes³, ¹Cohen Children's Medical Center, Northwell Health, New Hyde Park, NY, ²Northwell Health, New York, NY, ³Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁴Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁵Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY
Background/Purpose: Pediatric lupus (pSLE) is a multisystemic autoimmune disease characterized by autoantibody production leading to organ damage. Neutrophil extracellular traps (NETs) are considered a potential…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].